FY2025 EPS Estimates for CVRx Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimates for CVRx, lowering the forecast from ($1.97) to ($1.99).
• CVRx reported a quarterly loss of ($0.57) per share, missing the analysts' consensus estimate of ($0.52), but the company achieved revenue of $13.59 million, exceeding expectations.
• Currently, the consensus rating for CVRx is "Moderate Buy" with an average target price of $14.00 per share, amid varying ratings from other analysts.

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Cantor Fitzgerald cut their FY2025 earnings estimates for shares of CVRx in a report released on Wednesday, August 6th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.99) per share for the year, down from their prior estimate of ($1.97). Cantor Fitzgerald currently has a "Overweight" rating and a $11.00 target price on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. Cantor Fitzgerald also issued estimates for CVRx's FY2026 earnings at ($1.88) EPS.

CVRX has been the subject of several other research reports. Piper Sandler dropped their price target on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. reissued an "underweight" rating and set a $7.00 price target (down previously from $15.00) on shares of CVRx in a research report on Friday, May 9th. Finally, William Blair upgraded shares of CVRx to a "strong-buy" rating in a report on Monday, July 7th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $14.00.

CVRx Trading Up 2.7%

Shares of CVRx stock traded up $0.21 during trading on Friday, reaching $7.72. The company's stock had a trading volume of 74,939 shares, compared to its average volume of 326,016. CVRx has a 52-week low of $4.30 and a 52-week high of $18.55. The company has a market cap of $201.75 million, a price-to-earnings ratio of -3.69 and a beta of 1.27. The firm's 50-day moving average is $6.92 and its two-hundred day moving average is $9.15. The company has a quick ratio of 10.78, a current ratio of 11.99 and a debt-to-equity ratio of 0.85.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The business had revenue of $13.59 million during the quarter, compared to analysts' expectations of $13.22 million.

Insider Activity

In other news, Director Kirk G. Nielsen acquired 61,200 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The shares were bought at an average cost of $5.23 per share, with a total value of $320,076.00. Following the transaction, the director owned 1,899,168 shares of the company's stock, valued at $9,932,648.64. This trade represents a 3.33% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 18.90% of the stock is currently owned by insiders.

Institutional Trading of CVRx

Several institutional investors have recently bought and sold shares of the company. Parkman Healthcare Partners LLC grew its position in CVRx by 33.5% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company's stock valued at $15,037,000 after purchasing an additional 308,348 shares during the last quarter. JPMorgan Chase & Co. grew its position in CVRx by 10,520.1% during the 4th quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock valued at $7,960,000 after purchasing an additional 622,370 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in CVRx during the 1st quarter valued at about $4,852,000. Geode Capital Management LLC grew its position in CVRx by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company's stock valued at $2,249,000 after purchasing an additional 23,079 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC purchased a new stake in CVRx during the 4th quarter valued at about $4,713,000. 75.27% of the stock is owned by hedge funds and other institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.